Collinsonia Canadensis Extract

Collinsonia Canadensis Extract and pregnancy

Caution Advised

Collinsonia Canadensis Extract comes from stone root, a plant traditionally used in herbal medicine for various purposes including circulatory support. In cosmetics, it serves as an astringent to tighten pores and soothe skin. There is no published research on the safety of topical Collinsonia Canadensis Extract during pregnancy. In herbal medicine contexts, stone root has been used historically for conditions like hemorrhoids and varicose veins, but internal use during pregnancy is not well-studied. The concern with botanical extracts during pregnancy is that they can contain multiple bioactive compounds whose effects on fetal development are unknown. Without safety data specific to pregnancy, conservative dermatologists often recommend avoiding lesser-known botanical extracts during pregnancy, especially in the first trimester. Given the absence of pregnancy safety data and the general principle of avoiding unstudied botanicals during pregnancy, this ingredient falls into the medium-risk category. While there is no evidence of harm, there is also no evidence of safety. ACOG recommends caution with herbal products during pregnancy. Pregnant women who prefer well-studied ingredients should choose alternatives. Those who continue using products with this ingredient should monitor for any unusual reactions.

Collinsonia Canadensis Extract and breastfeeding

Safe to Use

Collinsonia Canadensis Extract is used topically as an astringent in skincare products. There is no research on whether components of this plant extract can be absorbed systemically or transferred to breast milk. Given the topical route of administration and typical use in leave-on cosmetic products at low concentrations, systemic absorption is likely minimal. While the extract has not been studied specifically in breastfeeding, most botanical astringents applied to facial skin do not pose milk transfer risks due to limited penetration. Breastfeeding mothers can likely use this ingredient with low risk, though the lack of safety data means it cannot be rated as completely safe. Women who prefer extensively studied ingredients may choose more established astringents like witch hazel. As with all cosmetics, avoid applying products to the breast area before breastfeeding.

Collinsonia Canadensis Extract and postpartum

Safe to Use

Collinsonia Canadensis Extract functions as an astringent that can help tighten pores and control oil. For postpartum women not breastfeeding, there are no specific concerns related to this life stage. The ingredient may help address skin changes like increased oiliness or enlarged pores that some women experience postpartum due to hormonal shifts. However, given limited safety data, those with sensitive postpartum skin might prefer better-studied alternatives. The extract is generally well-tolerated when used topically.

Collinsonia Canadensis Extract and trying to conceive

Safe to Use

Collinsonia Canadensis Extract is a botanical astringent used topically in skincare. There is no evidence or known mechanism by which topical application would affect fertility, hormone balance, or conception. While the extract has not been specifically studied in women trying to conceive, its topical cosmetic use at low concentrations is unlikely to have systemic effects. Women who prefer to use only well-researched ingredients during the preconception period may choose alternatives, but there is no compelling reason to avoid this ingredient when trying to conceive. No fertility guidelines identify this botanical as a concern.

Collinsonia Canadensis Extract and PCOS

Safe to Use

Collinsonia Canadensis Extract serves as a natural astringent that can help regulate oil production and tighten pores. It has no known hormonal activity or effects on androgen or insulin pathways relevant to PCOS. The astringent properties may be beneficial for women with PCOS who experience oily skin and enlarged pores due to elevated androgens. By helping control sebum and tighten pores, this ingredient can improve the appearance of oily, acne-prone skin common in PCOS. Women with PCOS can safely use this ingredient, and it may offer cosmetic benefits for hormone-related skin concerns. However, those with sensitive skin or active acne should introduce it gradually, as astringents can sometimes be drying. The ingredient does not affect PCOS hormone levels or systemic symptoms.

Collinsonia Canadensis Extract and general use

Safe to Use

Collinsonia Canadensis Extract is a botanical astringent used in toners, serums, and treatments for oily or combination skin. It helps tighten pores and provide a mattifying effect while offering mild soothing properties. As a less common botanical ingredient, there is limited published research on its cosmetic safety profile. However, adverse reactions appear to be rare in practice. Those with sensitive skin or known plant allergies should patch test products containing this extract. Most users tolerate it well when used in properly formulated products. This ingredient is considered safe for general cosmetic use, though its relative novelty in mainstream skincare means it lacks the extensive safety database of more common astringents. It offers a natural option for oil control and pore refinement, making it suitable for normal to oily skin types.

Everything else flagged for the same profiles

• Flagged in pregnancy

Related ingredients

Ingredients suggested in place of Collinsonia Canadensis Extract, each one with its own page here.

• Niacinamide

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on 15 September 2026.